Literature DB >> 29290125

Management of Common Side Effects of Apremilast.

Annie Langley1, Jennifer Beecker1,2,3.   

Abstract

Apremilast is a relatively new therapy for the treatment of moderate to severe plaque psoriasis in adults. While this medication is considered safe with a very low risk of serious side effects, a few common (≥5% of patients) mild to moderate side effects have been reported, including diarrhea, nausea, headache, and nasopharyngitis. Not addressing these symptoms may lead to medication nonadherence and unnecessary discontinuation of therapy. These side effects are often easily managed with interventions available to the practicing dermatologist, and in only rare instances will these side effects require dose adjustment or discontinuation of therapy. The purpose of this article is to review common side effects of apremilast at its approved dose of 30 mg orally twice daily (BID) and to provide clear, simple recommendations for their management in dermatological practice.

Entities:  

Keywords:  adverse events; apremilast; psoriasis

Mesh:

Substances:

Year:  2017        PMID: 29290125     DOI: 10.1177/1203475417748886

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  5 in total

1.  Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin.

Authors:  Paulo Sarango-Granda; Lupe Carolina Espinoza; Natalia Díaz-Garrido; Helen Alvarado; María J Rodríguez-Lagunas; Laura Baldomá; Ana Calpena
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

2.  COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.

Authors:  A Pacifico; A d'Arino; P D M Pigatto; P Malagoli; G Damiani
Journal:  Clin Exp Dermatol       Date:  2021-06-09       Impact factor: 4.481

3.  An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India.

Authors:  Vishalakshi Viswanath; Pradnya Joshi; Prakash Lawate; Dakshata Tare; Dhiraj Dhoot; Namrata Mahadkar; Hanmant Barkate
Journal:  Psoriasis (Auckl)       Date:  2022-04-22

Review 4.  Apremilast in Paediatric Dermatoses - A Comprehensive Review.

Authors:  Nibedita Patro; Maitreyee Panda; Mrityunjay Dash; Anupam Das
Journal:  Indian J Dermatol       Date:  2022 Mar-Apr       Impact factor: 1.757

5.  Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients.

Authors:  Raphaella Cohen-Sors; Anne-Claire Fougerousse; Ziad Reguiai; Francois Maccari; Emmanuel Mahé; Juliette Delaunay; Aude Roussel; Maud Amy de la Breteque; Caroline Cottencin; Antoine Bertolotti; Hélène Kemp; Guillaume Chaby
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.